Patent-pending HA Platform

Licensing Opportunities for Proprietary Hyaluronic Acid Technologies

Patent-pending technologies designed for joint health, injectable therapeutics, and advanced HA formulations.
Request Licensing Discussion

Patent Pending

Joint Applications

Ready for Licensing

Seeking commercial partners

Actively pursuing licensing and co-development relationships.

Target Market

Orthopedic HA

technology stage

patent pending

Patent pending

Commercial Model

Licensing
Co-development

licensing

co-development

Patent Portfolio

Explore Studio Bioscience’s patent portfolio by status, application area, and available territories.

Issued Patent

Aesthetic Injectables

Status

Issued

Rights

  • Licensed US
  • Licensed Latin America

Available Territories

Canada

US

Patent Pending

Joint Applications

Status

Patent Pending

Priority Opportunity

  • Available Worldwide

Available Territories

Canada

US

Filter by Status

Filter by Application Area

Primary Licensing Opportunity

Partner With Studio Bioscience

Viscosupplementation

Injectable Therapies

Orthopedics

Sports Medicine

Joint Health

HA Formulations

Medical Devices

Commercialization

Technology Applications

ARC technology is relevant across a range of advanced HA-based medical and injectable applications.

Joint Health

Orthopedic Injectables

Viscosupplementation

Sports Medicine

HA Therapeutics

Injectables

Medical Devices

Regenerative Medicine

Worldwide Availability

Territorial availability varies by technology, field of use, and existing licensing arrangements.

Licensed

Available

Strategic Interest

US

Available

Canada

Available

Asia

Strategic Interest

Availability is subject to confirmation of existing agreements, field restrictions, patent coverage, and territorial rights.

Aesthetic Injectable Experience

HA-based injectable technologies developed for differentiated aesthetic applications.

Licensed

United States

Canada

Available

Europe

Canada

Strategic collaborations may be considered in selected Asian markets.

  • Availability remains subject to existing agreements, field restrictions, and confirmation of territorial rights.

Ophthalmic Experience

Broader HA formulation experience adapted to viscosity, stability, comfort, and manufacturing requirements.

1

Formulation Design

2

Optimization

3

Partner Development

4

Commercial Product

  • This ophthalmic formulation belongs to the partner company and is not currently available for licensing.

Ideal Partner Profiles

Pharmaceutical Companies

Medical Device Companies

CDMOs

Orthopedic Companies

Sports Medicine

Regulatory Specialists

Injectable Manufacturers

Commercial Partners

Partnership Structures

1

Exclusive Licensing

2

Regional Licensing

3

Co-development

4

Technology Transfer

5

Strategic Partnership

6

Platform Integration

Business Development Contact

Jacqueline Khayat, MBA

Chief Business Development Officer

Studio Bioscience

Request Licensing Discussion
Schedule Introductory Call

Advance the Next Generation of HA Technologies

Studio Bioscience is actively engaging qualified partners for licensing, co-development, and manufacturing discussions.

Contact Studio Bioscience